Martínez-Canabal A, Rivas-Arancibia S

Language: Spanish
References: 20
Page: 210-216
PDF size: 104.24 Kb.

Text Extraction

No abstract

REFERENCES

1. Roth GJ, Stanford N, Majerus PW. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci U S A 1975; 72: 3073-3076.

2. Hla T, Neilson K. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci U S A 1992; 89: 7384-7388.

3. Li L, Prabhakaran K, Shou Y, Borowitz JL, Isom GE. Oxidative stress and cyclooxygenase-2 induction mediate cyanide-induced apoptosis of cortical cells. Toxicol Appl Pharmacol 2002; 185: 55-63.

4. FitzGerald GA. COX-2 and beyond: Approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov 2003; 2: 879-890.

5. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev 1999; 79: 1193-1226.

6. Rall JM, Mach SA, Dash PK. Intrahippocampal infusion of a cyclooxygenase-2 inhibitor attenuates memory acquisition in rats. Brain Res 2003; 968: 273-276.

7. Schiltz JC, Sawchenko PE. Distinct brain vascular cell types manifest inducible cyclooxygenase expression as a function of the strength and nature of immune insults. J Neurosci 2002; 22: 5606-5618.

8. Mouihate A, Boisse L, Pittman QJ. A novel antipyretic action of 15-deoxy-Delta12,14-prostaglandin J2 in the rat brain. J Neurosci 2004; 24: 1312-1318.

9. Matsumura H, Nakajima T, Osaka T et al. Prostaglandin D2-sensitive, sleep-promoting zone defined in the ventral surface of the rostral basal forebrain. Proc Natl Acad Sci U S A 1994; 91: 11998-12002.

10. Satoh S, Matsumura H, Suzuki F, Hayaishi O. Promotion of sleep mediated by the A2a-adenosine receptor and possible involvement of this receptor in the sleep induced by prostaglandin D2 in rats. Proc Natl Acad Sci U S A 1996; 93: 5980-5984.

11. Yoshida H, Kubota T, Krueger JM. A cyclooxygenase-2 inhibitor attenuates spontaneous and TNF-alpha-induced non-rapid eye movement sleep in rabbits. Am J Physiol Regul Integr Comp Physiol 2003; 285: R99-109.

12. Consilvio C, Vincent AM, Feldman EL. Neuroinflammation, COX-2, and ALS—a dual role? Exp Neurol 2004; 187: 1-10.

13. Rich JB, Rasmusson DX, Folstein MF, Carson KA, Kawas C, Brandt J. Nonsteroidal anti-inflammatory drugs in Alzheimer’s disease. Neurology 1995; 45: 51-55.

14. Luterman JD, Haroutunian V, Yemul S et al. Cytokine gene expression as a function of the clinical progression of Alzheimer disease dementia. Arch Neurol 2000; 57: 1153-1160.

15. Bazan NG, Colangelo V, Lukiw WJ. Prostaglandins and other lipid mediators in Alzheimer’s disease. Prostaglandins Other Lipid Mediat 2002; 68-69: 197-210.

16. Butterfield DA, Howard BJ, LaFontaine MA. Brain oxidative stress in animal models of accelerated aging and the age-related neurodegenerative disorders, Alzheimer’s disease and Huntington’s disease. Curr Med Chem 2001; 8: 815-828.

17. Teismann P, Vila M, Choi DK et al. COX-2 and neurodegeneration in Parkinson’s disease. Ann N Y Acad Sci 2003; 991: 272-277.

18. Teismann P, Ferger B. Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson’s disease. Synapse 2001; 39: 167-174.

19. Yasojima K, Tourtellotte WW, McGeer EG, McGeer PL. Marked increase in cyclooxygenase-2 in ALS spinal cord: implications for therapy. Neurology 2001; 57: 952-956.

20. Siegel JM. Why we sleep. Sci Am 2003; 289: 92-97.